USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Optimal Synergy Between Leading-edge Computational Science and Therapeutics Development
13-Nov-2018
Global
Technology Research
D815-01-00-00-00
HC03105-GL-TR_22531
The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approaches, are extensively enlighten drug discovery and development landscape for the effective treatment of diseases. AI is pursued to provide the best suited approach to leverage scientific literature, patient’s omics-data and overall clinical data, to drive smart decisions.
1.1 Pharmaceutical Industry – Facts and Concerns
1.2 Research Focus: Forwarding New Therapeutics
1.3 Research Scope: Unveiling AI-driven Technology
1.4 Analysis Framework: Frost & Sullivan Core Value
1.5 Research Methodology: Five Steps Toward Success
2.1 Key Elements of Analysis: The ‘AI’ Concept
2.2 Brief Overview of AI in the Pharmaceutical Industry
2.3 The Evolution of Artificial Intelligence
2.4 The Science and Engineering Behind AI
2.5 Deep Learning and Machine Learning Approaches
3.1 Growth Opportunities for AI Strategic Imperatives
3.2 AI Technology Segmentation
3.3 Additional AI Technology Segmentation
3.4 AI-driven Evolution in Healthcare Applications
3.5 AI-driven Pharmaceutical Applications
3.6 Utilization of AI-driven Databases
4.1 Companies Succeeding in AI-driven Drug Development
4.2 Companies Succeeding in AI-driven Data Leverage
5.1 AI-based Therapeutics Value Chain and Participants
5.2 Frost & Sullivan’s Assessment Methodology
5.3 Frost & Sullivan’s Innovation Identification
5.4 Technology Transfer Assessment and Perceptions
6.1 Berg: Innovation Dashboard
6.2 Berg: Process Qualification
6.3 Berg: Application Prioritization
6.4 Berg: Main Prioritization Features
6.5 BenevolentAI: Innovation Dashboard
6.6 BenevolentAI: Process Qualification
6.7 BenevolentAI: Application Prioritization
6.8 BenevolentAI: Main Prioritization Features
6.9 Kyndi: Innovation Dashboard
6.10 Kyndi: Innovation Framework
6.11 Kyndi: Process Qualification
6.12 Kyndi: Application Prioritization
6.13 Kyndi: Main Prioritization Features
6.14 Evid Science: Innovation Dashboard
6.15 Evid Science: Process Qualification
6.16 Evid Science: Application Prioritization
6.17 Evid Science: Main Prioritization Features
6.18 ReviveMed: Innovation Dashboard
6.19 ReviveMed: Process Qualification
6.20 ReviveMed: Application Prioritization
6.21 ReviveMed: Main Features Prioritization
6.22 Structura Bio: Innovation Dashboard
6.23 Structura Bio: Process Qualification
6.24 Structura Bio: Application Prioritization
6.25 Structura Bio: Main Features Prioritization
6.26 AcuraStem: Innovation Dashboard
6.27 AcuraStem: Process Qualification
6.28 AcuraStem: Application Prioritization
6.29 AcuraStem: Main Features Prioritization
6.30 FDNA: Innovation Dashboard
6.31 FDNA: Process Qualification
6.32 FDNA: Application Prioritization
6.33 FDNA: Main Features Prioritization
6.34 Innoplexus: Innovation Dashboard
6.35 Innoplexus: Process Qualification
6.36 Inoplexus: Application Prioritization
6.37 Innoplexus: Main Features Prioritization
6.38 Biovista: Innovation Dashboard
6.39 Biovista: Process Qualification
6.40 Biovista: Application Prioritization
6.41 Biovista: Main Features Prioritization
6.42 Standigm: Innovation Dashboard
6.43 Standigm: Process Qualification
6.44 Standigm: Application Prioritization
6.45 Standigm: Main Features Prioritization
7.1 Funding and Investment Models and Adoption
7.2 Funding and Investment Trends
7.3 Partnership Collaborations Advancing AI Pharma
7.4 Companies Raising Funding for AI Developments
8.1 Technology Maturity Level and Description
8.2 Roadmap Tapping into Technology Synergy
8.3 Business Model Hybridization
8.4 Future Perspective for AI-driven Therapeutics
9.1 Industry Interactions (continued)
9.1 Industry Interactions (continued)
9.1 Industry Interactions (continued)
9.1 Industry Interactions (continued)
9.1 Industry Interactions (continued)
10.1 Frost & Sullivan’s Coverage: Ongoing Research
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Industries | Healthcare |
| WIP Number | D815-01-00-00-00 |
| Is Prebook | No |
Artificial Intelligence Revolutionizing the Pharmaceutical Industry
$4,950.00
Special Price $3,712.50 save 25 %